AJAC  Vol.5 No.2 , January 2014
Spectrophotometric Determination of Etravirine in Bulk and Pharmaceutical Formulations
Abstract: Two simple, rapid, sensitive, accurate, precise and economical Visible Spectrophotometric methods have been developed for the determination of Etravirine in pure and pharmaceutical formulations. These methods (A and B) were based on nucleophilic substitution and oxidative coupling reactions of Etravirine by 1,2-naphtha quinone-4-sulphonate (NQS) in alkaline medium and 3-methyl-2-benzothiazolinone hydrazone (MBTH) in acidic medium with the maximum absorbance at 414 nm and 635 nm respectively. Linearity was obtained in the concentration range of 5 -30 μg/ml and 2 -10 μg/ml which was corroborated by the correlation coefficient (r) values of 0.9995 and 0.9996 respectively. The methods developed were validated with respect to linearity, accuracy (recovery), precision, Sandell’s sensitivity, molar extinction coefficient and specificity. The proposed methods are successfully applied for the determination of Etravirine in bulk and pharmaceutical formulations and results were validated statistically by recovery studies.
Cite this paper: D. Murali, S. Venkatrao and C. Rambabu, "Spectrophotometric Determination of Etravirine in Bulk and Pharmaceutical Formulations," American Journal of Analytical Chemistry, Vol. 5 No. 2, 2014, pp. 77-82. doi: 10.4236/ajac.2014.52012.

[1]   A. I. Maiga, D. Descamps, L. Morand-Joubert, I. Malet, A. Derache, M. Cisse, V. Koita, A. Akonde, B. Diarra, M. Wirden, A. Tounkara, Y. Verlinden, C. Katlama, D. Costagliola, B. Masquelier, V. Calvez and A.-G. Marcelin, “Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naive Patients Infected with Non-B HIV-1 Subtypes,” Antimicrobial Agents and Chemotherapy, Vol. 54, No. 2, 2010, pp. 728-733.

[2]   J. D. Croxtall, “Etravirine: A Review of Its Use in the Management of Treatment-Experienced Patients with HIV-1 Infection,” Drugs, Vol. 72, No. 6, 2012, pp. 847-869.

[3]   J. M. Tiraboschi, J. Niubo, A. Vila, S. Perez-Pujol and D. Podzamczer, “Etravirine Concentrations in CSF in HIV-Infected Patients,” Journal of Antimicrobial Chemotherapy, Vol. 67, No. 6, 2012, pp. 1446-1448.

[4]   A. Gutiérrez-Valencia, R. Martin-Pena, A. Torres-Cornejo, R. Ruiz-Valderas, J. R. Castillo-Ferrando and L. F. López-Cortés, “Intracellular and Plasma Pharmacokinetics of 400 mg of Etravirine Once Daily versus 200 mg of Etravirine Twice Daily in HIV-Infected Patients,” Journal of Antimicrobial Chemotherapy, Vol. 67, No. 3, 2012, pp. 681-684.

[5]   C. V. Abobo, L. Wu, J. John, M. K. Joseph, T. R. Bates and D. Liang, “ LC-MS/MS Determination of Etravirine in Rat Plasma and Its Application in Pharmacokinetic Studies,” Journal of Chromatography B, Analaytical Technologies in the Biomed Life Sciences, Vol. 878, No. 36, 2010, pp. 3181-3186.

[6]   S. Quaranta, C. Woloch, A. Paccou, M. Giocanti, C. Solas and B. Lacarellere, “Validation of an Electrospray Ionization LC-MS/MS Method for Quantitative Analysis of Raltegravir, Etravirine, and 9 Other Antiretroviral Agents in Human Plasma Samples,” Therapeutic Drug Monitoring, Vol. 31, No. 6, 2009, pp. 695-702.

[7]   N. L. Rezk, N. R. White, S. H. Jennings and A. D. M. Kashuba, “A Novel LC-ESI-MS Method for the Simultaneous Determination of Etravirine, Daunavir and Ritonavir in Human Blood Plasma,” Talanta, Vol. 79, No. 5, 2009, pp. 1372-1378.

[8]   A. Fayet, A. Benguin, B. Zanolari, S. Lruchon, N. Guiguard, A. Telenti, M. Cavassani, H. F. Gunthard, T. Buclin, J. Biollaz, B. Rochat and L. A. Decosterd, “A LCTandem MS Assay for the Simultaneous Measurement of New Anti Retroviral Agents: Raltegravir, Maraviroc, Darunavir, and Etravirine,” Journal of Chromatography B, Vol. 877, No. 11-12, 2009, pp. 1057-1069.

[9]   A. D’Avolio, M. Simiele, M. Siccardi, L. Baietto, M. Sciandra, V. Oddone, F. R. Stefani, S. Aqati, J. Cusato, S. Bonora and G. Diperri, “HPLC-MS Method for the Simultaneous Quantification of Fourteen Antiretroviral Agents in Peripheral Blood Mono Nuclear Cell of HIV Infected Patients Optimized Using Medium Corpuscular Volume Evaluation,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 54, No. 4, 2011, pp. 779-788.

[10]   A. D’Avolio, M. Simiele, M. Siccardi, L. Baietto, M. Sciandra, S. Bonora and G. Diperri, “HPLC-MS Method for the Quantification of Nine Anti HIV Drugs from Dry Plasma Spot on Glass Filter and Their Long Stability in Different Conditions,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 52, No. 5, 2010, pp. 774-780.

[11]   A. D’Avolio, L. Baietto, M. Sciandra, M. Siccardi, M. Simiele, V. Oddone, S. Bonora and G. Diperri, “An HPLCPDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New NNRTI Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients,” Therapeutic Drug Monitoring, Vol. 30, No. 6, 2008, pp. 662-669.

[12]   A. Hirano, M. Takahashi, E. Konoshita, M. Shibata, T. Nomura, Y. Yokomaku, M. Hamaguchi and W. Sugiura, “High Performance Liquid Chromatography Using UV Detection for the Simultaneous Quantification of the Non-Nucleoside Reverse Transcriptase Inhibitor Etravirine (TMC-125), and 4 Protease Inhibitor in Human Plasma,” Biological and Pharmaceutical Bulletin, Vol. 33, No. 8, 2010, pp. 1426-1429.

[13]   C. H. Venkata Reddiah, P. Rama Devi, K. Mukkanti and S. Katari, “Estimation of Etravirine by UV-Visible Spectrophotometric Method in Tablet Dosage Forms and Its in Vitro Dissolution Assessment,” International Journal of Pharmaceutical Research and Development, Vol. 3, No. 3, 2012, pp. 287-295.

[14]   S. S. Panda, B. V. V. Ravikumar and D. Patanaik, “Spectrophotometric Determination of Alendronate Sodium by using Sodium-1,2-Naphthaquinone-4-Sulphonate,” International Journal of Pharmaceutical Sciences and Nanotechnology, Vol. 4, No. 2, 2012, pp. 1563-1568.

[15]   A. Biksham Babu, G. Ramu, S. Venkata Rao, T. Neeharika and C. Rambabu, “Spectrophotometric Determination of an Antiretroviral Drug Stavudine in Bulk and Pharmaceutical Formulations,” Rasayan Journal of Chemistry, Vol. 4, No. 2, 2011, pp. 336-342.